Articles On Neuren Pharmaceuticals (ASX:NEU)

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

It's been yet another pleasing day for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, giving ASX shares a three-for-three winning streak for the week thus far. The ASX 200 put...

The S&P/ASX 200 Index (ASX: XJO) is in fine form on Tuesday. In afternoon trade, the benchmark index is up 1.2% to 7,054.2 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why they a...

The S&P/ASX 200 Index (ASX: XJO) has finally cracked its run of negativity and given investors a positive day today. After falling every single day this week thus far, the ASX 200...

ASX closes higher as Wall Street rebounds and US bond yields retreat on weaker jobs data Lithium miners fall as J.P. Morgan downgrades sector after reviewing lithium price outlook Life 360 and Xero higher as tech sector rallies along with...

If you're in the market for some new ASX shares this month, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for October. Two on list this month are...

The S&P/ASX 200 Index (ASX: XJO) has just endured a horror day as investors scramble for the exits amid widespread fears over ASX sales. By the end of today's trading, the ASX 200 ha...

ASX slips to 100-day low as climbing US 10-year bond yields weigh on global markets RBA keeps rates on hold but new governor Michele Bullock hasn’t ruled out further hikes CSL leads healthcare higher after Morgan Stanley puts an overweigh...

With apologies to Charles Dickens, it’s the best of times and the worst of times for wound care house Next Science (ASX:NXS) as it shapes itself up for a renewed market assault under a new CEO. On the positive side of the ledger, the compan...

It's been yet another day of falls for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Thursday, making it the third of four days this week that have seen losses. The ASX 200 chec...

The S&P/ASX 200 Index (ASX: XJO) has once again given investors a headache this Wednesday, as the index recorded yet another day in the red. Following yesterday's sell-off, the ASX 200...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotif...

It's been another sad day for the S&P/ASX 200 Index (ASX: XJO) this Tuesday. After the rough start to the trading week the ASX 200 gave us yesterday, investors were probably hoping for a rec...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

For me, earnings without guidance is a bit like pizza without cheese – little more than cooked tomato paste on flatbread. And I don’t buy it. Macquarie Bank analysts who know more and are paid better for it, said – in their end of season AS...

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

Harvey Norman booted out of S&P ASX 100 as lithium play Liontown Resources admitted 2023 market darling of ASX biotech sector Neuren Pharmaceuticals a new addition to S&P ASX 200 The scent of blooming flowers, a gentle warming sun...

It’s that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&P/ASX Indices. According to the release, there will be a total of five companies entering the S&P/ASX 200 Index (ASX: XJO) at the n...

ASX health sector rises in line with broader markets as reporting season comes to end EBR Systems on schedule for key US FDA submission in Q1 CY24 for (WiSE) CRT system Health imaging company Mach7 achieves record sales order book of $40.3...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))...

ASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 8% over the past year. By comparison, the market benchmark S&P/ASX 200 Index (ASX: XJO) is u...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Peak Asset M...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia.   What sector is hot r...

ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No...

ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun...

ASX 200 climbed to a 100-day high  Energy and Mining retreated after a flurry of earnings reports Fortescue Metals fell despite delivering at the top end of guidance   Local shares jumped by another 0.75% on Wednesday, touching a 100-day...

ASX-listed AusBiotech member Neuren Pharmaceuticals (ASX:NEU) has received the Blake Award for Excellence after a successful year, including an FDA approval and key commercial partnerships.

The ASX 200 built a platform for success today. Which failed. It fell flat at close Sectors wise, Financials, IT and Industrials did okay. The others, very much including Health Care and Utilities, didn’t Notable performers today: Nuix (AS...

These are the stories that are the stuff of dreams for every single ASX All Ords shares investor. Buying at the exact right time… to capture extraordinary share price growth… in a very short period. So hard to do. But we love the stories...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decline. At the time of writing, the benchmark index is down 0.35% to 7,271.9 points. Four ASX shares that are not letting that hold them back are listed be...

Neurotech is following in the footsteps of 2023 market darling of the ASX biotech sector Neuren with another possible treatment for Rett Syndrome. Biopharmaceutical company Neurotech International (ASX:NTI) has hopes of becoming the world’...

Neuren Pharmaceuticals (ASX:NEU) has announced the global expansion of its partnership with US company Acadia Pharmaceuticals for DAYBUE (trofinetide).

The ASX will open flattish as Wall Street finished modestly lower on Friday US banks were mixed following Q2 results The current tech rally is “not the dotcom bubble”, says analyst   Aussie shares are poised to open flattish on Monday fol...

ASX health stocks fall in  past five days with Power noting larger names trading on attractive valuations  Neuren Pharmaceuticals has expanded its current licensing agreement with Acadia Pharmaceuticals Pharmaxis reports positive results f...

Junior biotech Neuren Pharmaceuticals has signed an expanded licensing deal with its US distribution partner Acadia to expand the sale of its drug Daybue to global markets, pushing its stock price up by 16.24% today, trading at $13.53 per...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a high. At the time of writing, the benchmark index is up 0.9% to 7,312.5 points. Four ASX shares that are climbing more than most today are listed b...

ASIC plans to establish a stakeholder advisory group to oversee ASX's troubled CHESS replacement project, which ASX supports and sees as a means to enhance transparency and stakeholder engagement in the development of critical clearing and...

Neuren Pharma share price jumps after extending partnership deal with Acadia Acadia will now be the exclusive licence holder for DAYBUE globally Neuren is set to receive hundreds of million of dollars in milestone payments   Market darlin...

Neuren Pharmaceuticals (NEU) receives $145 million from its partner Acadia Pharmaceuticals to expand its North American drug license of trofinetide into global markets The company also stands to make up to $620 million from ongoing miles...

  Neuren Pharmaceuticals (ASX:NEU) announced the expansion of its partnership with Acadia Pharmaceuticals (NASDAQ:ACAD). Neuren is set to receive US$100 million up-front, plus additional potential milestone payments of up to US$427 million,...

Magnis Energy Technologies Ltd (ASX: MNS) shares won’t be going anywhere again on Friday. That’s because this vertically integrated lithium-ion battery technology and materials company’s shares have been in a trading halt since yeste...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is on course to end the week on a very positive note. In early trade, the pharmaceuticals company’s shares are up 26% to $14.69. This means its shares are now up 265% over the last 12...

Australian shares are set to open in the green after tech stocks rallied strong trade on Wall Street overnight and the Nasdaq topped the 4500 mark. Treasurer Jim Chalmers will break the news of Australia’s next RBA governor after a cabin...

14 Jul 2023 - A snapshot of the stocks on the move, featuring Neuren Pharmaceuticals (ASX:NEU), Green Technology Metals (ASX:GT1) and One Click Group (ASX:1CG).

ASX health stocks have fallen in the past five days in line with broader markets Mach7 wins a US$60 million Veterans contract – the most significant in its history Neuren completes recruitment for Phase II trial of NNZ-2591 in Phelan-McDer...

ASX All Ords shares closed out FY23 with a solid 8.85% gain but as shown in the chart below, it was a rollercoaster ride that most of us would never want to be on! The S&P/ASX All Ordinaries Index (ASX: XAO) experienced a tumultuous 1...

Neuren Pharmaceuticals (ASX:NEU) has announced that the first site in the US for its Phase 2 clinical trial of NNZ-2591 in Prader-Willi syndrome is now open.